Deerfield Management Company, L.P. (Series C) Supernus Pharmaceuticals, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $145,092 - $188,229	-5,352 Reduced 44.58%	6,654 $226,000
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $272,776 - $356,338	12,006 New	12,006 $347,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$376 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$222 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$185 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$104 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$95.3 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account